Introducing Olink Flex: Immuno-Oncology panel

While the ground breaking success of immunotherapy has revolutionized cancer treatment, efforts to better predict responses and increase efficacy while reducing toxicity remain key challenges in the oncology field. Patient profiling based on blood biomarkers can have significant clinical value, due to the capacity of circulating proteins to provide real-time insights in a non-invasive, robust, and efficient manner. Here, Olink presents the Olink Flex Immuno-Oncology panel, which includes 21 proteins involved in various facets of tumor development and the immune response. Some of these biomakrers, such as IL8, LIF, IL6, TNFa, IFNγ and CXCL9/10/11, have been shown as clinically relevant for stratifying patients treated with immune checkpoint inhibitors.